Search
Close this search box.

We are creating some awesome events for you. Kindly bear with us.

Machine Learning Unlocks the Potential of Antibodies

Image credits: ews.umich.edu
Getting your Trinity Audio player ready...

The University of Michigan has developed machine-learning algorithms technology. This new technology can identify problematic areas in antibodies, making them less susceptible to binding non-target molecules. This innovative development, led by Peter Tessier, the Albert Mattocks Professor of Pharmaceutical Sciences at U-M and the study’s corresponding author in Nature Biomedical Engineering, presents a ground-breaking solution to enhance the effectiveness of antibodies in fighting diseases.

“Antibodies play a crucial role in our immune system’s defence mechanism by binding to specific molecules known as antigens on disease-causing agents, such as the spike protein on the COVID-19 virus,” Tessier expressed, “Once bound, antibodies either directly neutralise harmful viruses or cells or signal the body’s immune cells to take action.”

However, there’s a challenge associated with antibodies designed to bind strongly and rapidly to their specific antigens. These antibodies may also bind to non-antigen molecules, leading to their premature removal from the body. Moreover, they can interact with other antibodies of the same type, forming dense solutions that do not easily flow through the needles used for delivering antibody drugs.

Tessier highlighted the importance of antibodies that can simultaneously perform three critical tasks: tightly binding to their intended target, repelling each other, and disregarding other substances within the body. Antibodies failing to meet all three criteria are unlikely to be successful drugs. Unfortunately, a significant number of clinical-stage antibodies fall short in this regard.

In their recent study, Tessier’s team assessed the activity of 80 clinical-stage antibodies in the laboratory. It made a startling discovery – 75% of these antibodies interacted with the wrong molecules, with each other, or both. To address this issue, the team turned to machine learning.

By making subtle changes to the amino acids that make up an antibody, they can alter the antibody’s three-dimensional structure. This modification helps prevent antibodies from behaving improperly, as an antibody’s structure determines the substances it can bind to. However, making changes without careful consideration can introduce more problems than they solve, and the typical antibody contains hundreds of amino acid positions that could be altered.

Fortunately, machine learning offers a streamlined solution. Tessier’s team created models that are trained using experimental data collected from clinical-stage antibodies. These models can precisely identify how to modify antibodies to ensure they meet all three criteria mentioned earlier, with an impressive accuracy rate of 78% to 88%. This approach significantly reduces the number of antibody modifications that chemical and biomedical engineers need to produce and test in the lab.

Tiexin Wang, a doctoral student in chemical engineering and a co-author of the study, emphasised the pivotal role of machine learning in accelerating drug development. This advanced technology is already attracting attention from biotech companies, which recognise its potential for optimising the development of next-generation therapeutic antibodies.

Tessier concluded by mentioning that some companies have developed antibodies with desirable biological activity but are aware of potential challenges when using these antibodies as drugs. In such cases, Tessier’s team steps in to identify specific areas within the antibodies that require modification, offering valuable assistance to these companies.

PARTNER

Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.

PARTNER

As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.

PARTNER

Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.

SUPPORTING ORGANISATION

SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.

PARTNER

HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 

PARTNER

IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.